Karo Pharma divests brand portfolio to Evolan Pharma prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.
Karo Pharma to sell its treasury shares
HUDDINGE, Sweden, May 6, 2021 /PRNewswire/ Karo Pharma ( Karo ) pursues a growth strategy, which combines geographical expansion with an active acquisition strategy. To execute on this strategy, Karo needs capital and a strong financial position. The treasury shares represent an unutilized resource in the company and a sale of the shares enhances Karo s financial flexibility. On October 30, 2020 Karo communicated its intentions to sell its treasury shares for the above purpose. This process has now been completed and Karo today announces the sale of all remaining (1,375,417) treasury shares, representing approximately 0.6% of the total number of shares and votes in Karo, to Karo Intressenter AB
Karo Pharma resolves on sale of own shares
HUDDINGE, Sweden, April 28, 2021 /PRNewswire/ Under the the authorization from the 2021 Annual General Meeting, the Board of Directors has resolved to sell up to 1,768,000 own shares to expand the company s financial flexibility. The sale of own shares shall be effected - on one or several occasions before the 2022 Annual General Meeting, where a new mandate should be requested if necessary - on Nasdaq Stockholm at a price within the effective registered price interval on Nasdaq Stockholm, such interval being the interval between the highest purchase price and the lowest sales price. The transfers shall be executed in accordance with Section 5.1.1 part H of the Nasdaq Issuer Rules and otherwise in accordance with all applicable rules and regulation.
Karo Pharma publishes the 2020 annual report prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.
Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals
News provided by
Share this article
Share this article
HUDDINGE, Sweden, Feb. 3, 2021 /PRNewswire/ Karo Pharma Aktiebolag ( Karo ) today announces the acquisition of an OTC brand portfolio containing Flux
®, Decubal
The transaction transfers ownership of the brand portfolio, comprised of Flux
®, Decubal
® and Fludent
® from Teva to Karo. The brands generated sales just short of EUR 35m in 2020 on a global basis. The majority is generated in the Nordic markets, including Scandinavia, where the brands already are distributed and marketed by Karo under a 7-year license agreement that was signed in the spring of 2019.